Lucid Diagnostics (LUCD) Gains from Investment Securities (2020 - 2026)

Lucid Diagnostics has reported Gains from Investment Securities for 7 years, with the latest figure at $17000.0 in Q1 2026.

• For the quarter ending Q1 2026, Gains from Investment Securities changed N/A year-over-year to $17000.0; the trailing twelve-month figure through Dec 2025 stood at $10.3 million (up 1649.15% YoY), and the FY2025 full-year result was $10.3 million, up 1649.15% from the prior year.
• Gains from Investment Securities for Q1 2026 stood at $17000.0, down from $10.3 million in the prior quarter.
• The five-year high for Gains from Investment Securities was $10.3 million in Q4 2025, with the low at $17000.0 in Q1 2026.
• Historically, Gains from Investment Securities has averaged $2.6 million across 5 years, with a median of $588977.0 in 2023.
• The largest YoY upside for Gains from Investment Securities was 1649.15% in 2025 against a maximum downside of 94.55% in 2025.
• Lucid Diagnostics' Gains from Investment Securities stood at $2.6 million in 2022, then jumped by 114.56% to $5.5 million in 2023, then sank by 89.33% to $587292.0 in 2024, then jumped by 1649.15% to $10.3 million in 2025, then tumbled by 99.83% to $17000.0 in 2026.
• The last three Gains from Investment Securities figures came in at $17000.0 (Q1 2026), $10.3 million (Q4 2025), and $472336.0 (Q3 2025), per Business Quant data.